Clinical trial · Interventional
CTC Pancreatic Adenocarcinoma
Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?
NCT02335151CI-TRIAL-00042249completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Proportion of circulating tumor cells (CTC) in the postoperative phase after curative tumor removal of pancreatic cancer will be determined and correlated to the accordance of anesthesia (desflurane versus propofol)
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Circulating Tumor Cells | — | UNRESOLVED | — |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Desflurane | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Desflurane
- description
- General anesthesia with Desflurane
- interventionNames
- Drug: Desflurane
- type
- NO_INTERVENTION
- label
- Propofol
- description
- General anesthesia with Propofol
Primary outcomes (1)
- measure
- Peak of CTC in the postoperative phase after curative tumor removal
- timeFrame
- Day 0 to Day 7
- description
- CTC will be counted and peak of CTC will be determined.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 to 85 * ASA I-III ( American Society of Anesthesiologists) * Resectable pancreatic adenocarcinoma * Primary surgery * No neoadjuvant therapy * Written informed consent Exclusion Criteria: * Metastatic disease * Other than primary surgery (recurrence, reconstruction) * Pre-operative chemotherapy * Chronic opioid use * Known hypersensitivity or suspected allergy to propofol, soya or egg proteins * Known hypersensitivity to volatile anaesthetics (malignant hyperthermia) * Pregnancy * Breast feeding * Enrolment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion
References
Publications (0)
Data not yet available
No reference posted for this study.